At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 66 enrolled
Drug / intervention
Necitumumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination With Abemaciclib in Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 1 clinical trial evaluating Necitumumab and Abemaciclib for Carcinoma, Non-Small-Cell Lung and Neoplasm Metastasis. Completed, enrolled 66 participants across 15 sites in 3 countries.
Detailed Summary
This is medical research evaluating the safety and efficacy of two new medicines (necitumumab and abemaciclib), administered in combination in participants affected by a defined type of advanced lung cancer (stage IV non-small-cell lung cancer).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, Spain
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJun 2015
Primary CompletionJun 2017
Study CompletionMay 2019
TodayJul 2026
First PostedApr 8, 2015
Enrollment StartJun 4, 2015
Primary CompletionJun 23, 2017
Study CompletionMay 28, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.2 years ago
Interventions
Necitumumabdrug
Administered IV.
Abemaciclibdrug
Administered orally.